| Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species SG Whaley, EL Berkow, JM Rybak, AT Nishimoto, KS Barker, PD Rogers Frontiers in microbiology 7, 231851, 2017 | 819 | 2017 |
| The β‐lactams strike back: Ceftazidime‐avibactam EJ Zasowski, JM Rybak, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35 (8 …, 2015 | 209 | 2015 |
| Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris JM Rybak, LA Doorley, AT Nishimoto, KS Barker, GE Palmer, PD Rogers Antimicrobial agents and chemotherapy 63 (4), 10.1128/aac. 00057-19, 2019 | 115 | 2019 |
| Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris JM Rybak, JF Muñoz, KS Barker, JE Parker, BD Esquivel, EL Berkow, ... MBio 11 (3), 10.1128/mbio. 00365-20, 2020 | 105 | 2020 |
| Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent JM Rybak, KR Marx, AT Nishimoto, PD Rogers Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35 (11 …, 2015 | 105 | 2015 |
| Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections KD Brade, JM Rybak, MJ Rybak Infectious diseases and therapy 5, 1-15, 2016 | 102 | 2016 |
| Mutations in hmg1, Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus JM Rybak, W Ge, NP Wiederhold, JE Parker, SL Kelly, PD Rogers, ... MBio 10 (2), 10.1128/mbio. 00437-19, 2019 | 89 | 2019 |
| Tedizolid phosphate: a next-generation oxazolidinone JM Rybak, K Roberts Infectious diseases and therapy 4, 1-14, 2015 | 89 | 2015 |
| Emerging threat of triazole-resistant Aspergillus fumigatus JM Rybak, JR Fortwendel, PD Rogers Journal of Antimicrobial Chemotherapy 74 (4), 835-842, 2019 | 63 | 2019 |
| Imipenem‐cilastatin‐relebactam: A novel β‐lactam–β‐lactamase inhibitor combination for the treatment of multidrug‐resistant gram‐negative infections JR Smith, JM Rybak, KC Claeys Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (4 …, 2020 | 61 | 2020 |
| Current and prospective treatments for multidrug-resistant gram-positive infections JM Rybak, KE Barber, MJ Rybak Expert opinion on pharmacotherapy 14 (14), 1919-1932, 2013 | 58 | 2013 |
| Loss of C-5 sterol desaturase activity results in increased resistance to azole and echinocandin antifungals in a clinical isolate of Candida parapsilosis JM Rybak, CM Dickens, JE Parker, KE Caudle, K Manigaba, SG Whaley, ... Antimicrobial agents and chemotherapy 61 (9), 10.1128/aac. 00651-17, 2017 | 56 | 2017 |
| Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance JM Rybak, K Marx, CA Martin Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34 (11 …, 2014 | 56 | 2014 |
| Mechanisms of triazole resistance in Aspergillus fumigatus AV Nywening, JM Rybak, PD Rogers, JR Fortwendel Environmental microbiology 22 (12), 4934-4952, 2020 | 51 | 2020 |
| In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris JM Rybak, KS Barker, JF Muñoz, JE Parker, S Ahmad, E Mokaddas, ... Clinical Microbiology and Infection 28 (6), 838-843, 2022 | 41 | 2022 |
| The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris JM Rybak, CA Cuomo, PD Rogers Current opinion in microbiology 70, 102208, 2022 | 32 | 2022 |
| Delineation of the Direct Contribution of Candida auris ERG11 Mutations to Clinical Triazole Resistance JM Rybak, C Sharma, LA Doorley, KS Barker, GE Palmer, PD Rogers Microbiology Spectrum 9 (3), e01585-21, 2021 | 31 | 2021 |
| Characterization of the efflux capability and substrate specificity of Aspergillus fumigatus PDR5-like ABC transporters expressed in Saccharomyces cerevisiae BD Esquivel, JM Rybak, KS Barker, JR Fortwendel, PD Rogers, TC White MBio 11 (2), 10.1128/mbio. 00338-20, 2020 | 26 | 2020 |
| Mutations in JM Rybak, JF Muñoz, KS Barker, JE Parker, BD Esquivel, EL Berkow, ... TAC1B, 2020 | 22 | 2020 |
| Utilizing Monte Carlo simulations to optimize institutional empiric antipseudomonal therapy SJ Tennant, DR Burgess, JM Rybak, CA Martin, DS Burgess Antibiotics 4 (4), 643-652, 2015 | 16 | 2015 |
Elizabeth L. BerkowCenters for Disease Control and PreventionEmail confirmado em cdc.gov
